The latest round of COVID-19 vaccines have been approved by the FDA. On Tuesday, the CDC will determine who should get the new shots....
For people suffering from long COVID's often disabling symptoms, including intense fatigue, breathing troubles, cognitive issues and heart palpitations, the list of scientific unknowns may sound defeating. There's still no validated treatment or diagnostic test specifically for the condition, although there are many candidates....
Being a clinical trial participant, especially in an interventional trial, is a sacrifice of time and body and represents a true commitment on the part of the patient....
Restrictive eligibility criteria has been a concern for many oncology researchers, who believe these trials should reflect a broader real-world population....
The UW School of Medicine and Public Health's Dr. Sterling Johnson recently joined Wisconsin Public Radio to discuss the Wisconsin Registry for Alzheimer's Prevention (WRAP) study at the University of Wisconsin-Madison....
The results of Eli Lilly's donanemab trial have lit a fire to Alzheimer's disease research but what else is on the horizon?...
Health-related discoveries in people can lead to better medical care for dogs. Likewise, studies of dog biology can lead to better understanding and treatments for people....
Just one dose of psilocybin significantly improved depression symptoms and functional disability in patients with major depressive disorder (MDD), a randomized trial found....
Are faster drug approvals by the FDA hurting the public's overall perception of clinical research?...
Commenters on the FDA's guidance on clinical investigations and drug development programs for psychedelic drugs raised concerns about decoupling drug administration from psychotherapy support, the proposed credentials for lead safety monitors and the agency’s characterization of the abuse potential of psychedelic drugs....
